Tag: NASDAQ:SHPG

September 12, 2019

5 Alzheimer’s Disease Treatment Stocks on the NASDAQ

A report from Reports and Data suggests the overall Alzheimer's market will be worth US$12.43 billion by 2026.
December 13, 2018

Pharma Trends 2018: Drug Pricing Takes Center Stage

Knowing what pharma trends influenced the market this year may be key for new and ongoing investing opportunities.
December 10, 2018

5 Top Biotech News Stories of 2018

The Investing News Network recaps 2018 with the five top biotech news stories of the year, according to our readers.
November 30, 2018

Shire Receives European Approval for TAKHZYRO (lanadelumab) subcutaneous injection

Shire (LSE:SHP, NASDAQ:SHPG), the leading global biotechnology company focused on rare diseases, today announced that the European Commission (EC) has...
November 20, 2018

Takeda and Shire Receive Major Acquisition Clearance

The European Union has given the acquisition conditional clearance. Conditions pertain to potential overlap between the companies' inflammatory bowel disease...
November 20, 2018

Shire: Phase I conditional clearance by the European Commission

Shire (NASDAQ:SHPG) announced the publication of a scheme document relating to the recommended cash and share offer being made by Takeda Pharmaceutical...
October 25, 2018

Shire Files Submission for U.S. FDA Approval to Manufacture FLEXBUMIN

Shire (LSE:SHP, NASDAQ:SHPG), the leading global biotechnology company focused on rare diseases, announced that it has filed its second submission...